Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05989958
Other study ID # HCB-201
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date September 22, 2023
Est. completion date September 2024

Study information

Verified date October 2023
Source Hexaell Biotech Co., Ltd.
Contact YU Chen, MD
Phone 86-13391663900
Email chybeyond@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, randomized, controlled, open-label phase 1/2 clinical study conducted in China to evaluate the efficacy, safety and tolerability of hiHep cell-based bio-artificial liver support system (HepaCure) plus DPMAS versus DPMAS alone in Chinese subjects with acute-on-chronic liver failure(ACLF). Phase 1 is a multicenter, open label study to evaluate the safety and tolerability of single dose and multiple doses of HepaCure with different treatment duration plus DPMAS in ACLF subjects respectively.


Recruitment information / eligibility

Status Recruiting
Enrollment 12
Est. completion date September 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Able to communicate effectively with investigators and sign the informed consent form (ICF) voluntarily. 2. Age: = 18 years and = 65 years. 3. Body weight: = 40kg; 4. Met the criteria of ACLF in the early and middle stages in screening period (Guidelines for the Diagnosis and Treatment of Liverfilture (2018 Edition)): base on chronic liver disease, acute jaundice deepened and coagulation dysfunction caused by various inducements, manifested as extreme fatigue, with obvious gastrointestinal symptoms such as anorexia, vomiting, abdominal distention, etc; Progressive deepening of jaundice, serum TBil = 171 µmol/L or increase = 17.1 µmol/L daily; with bleeding tendencies or manifestations (bleeding spots or ecchymosis), or 20%<PTA = 40% (or 1.5 = INR<2.6), and other reasons excluded. Exclusion Criteria: 1. Subjects with primary or metastatic liver cancer. 2. Subjects with severe esophageal/gastric varices and high risk of bleeding, with positive red signs, or with previous active bleeding, as indicated by gastroscopy or imaging examination results. 3. Pneumonia refer to the diagnostic criteria of the American Society of Infectious Diseases/American Thoracic Society for adult severe pneumonia in 2007), abdominal infection (after reasonable antibiotic treatment, there are still Peritonitis manifestations or white blood cells in ascites>0.1 × 10 9/L), etc. 4. Subjects with serious uncontrolled infections, including sepsis, septic shock, severe pneumonia (refers to the diagnostic criteria of the American Society of Infectious Diseases/American Thoracic Society for adult severe pneumonia in 2007), abdominal infection (exist Peritonitis manifestations or white blood cells in ascites>0.1 × 10 9/L after reasonable antibiotic treatment), etc;

Study Design


Intervention

Combination Product:
HepaCure
HepaCure will be administered in extracorporal dialysis for single dose or multiple doses with different treatment duration on top of DPMAS.

Locations

Country Name City State
China Beijing You'an Hospital affiliated to Capital Medical University Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Hexaell Biotech Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety outcome The adverse events (AE), Serious adverse event (SAE), adverse events of special concern (AESI), and device defects (leakage caused by the quality problem of the plasma biological purification column itself) of the safety paramater will be collected, and the safety and tolerability within 14 days and 28 days will be evaluated from the end of the last treatment 28 days after the end of last treatment
See also
  Status Clinical Trial Phase
Recruiting NCT03791190 - RCA for CRRT in Liver Failure and High Risk Bleeding Patients N/A
Completed NCT02557724 - Mobilization of Mesenchymal Stem Cells During Liver Transplantation
Recruiting NCT01698723 - A Trial of Ribavirin in Patients With ACLF Due to Hepatitis E Virus Phase 2
Completed NCT01404793 - SPME For Metabolomics And Concomitant Measurements Of Rocuronium Bromide Levels In Liver Transplantation N/A
Completed NCT01425385 - Autoregulation Assessment During Liver Transplantation N/A
Completed NCT03864497 - Myocardial Perfusion Imaging in Liver Transplantation Candidates
Completed NCT00808691 - Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit N/A
Completed NCT00287235 - Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS) N/A
Completed NCT03650920 - Hepatitis C Virus (HCV) Positive Liver Grafts in HCV Negative Recipients N/A
Recruiting NCT05517668 - Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose Phase 2
Recruiting NCT05726032 - Empagliflozin in Patients With Cirrhosis and Ascites Phase 2
Recruiting NCT04548596 - NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
Recruiting NCT02331745 - RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure Phase 4
Not yet recruiting NCT01961440 - Prognosis Scoring System for Acute-on-Chronic Liver Failure N/A
Active, not recruiting NCT01221454 - Allogenic Bone Marrow Stem Cell Transplantation in Liver Failure Phase 2
Completed NCT00772148 - Pharmacokinetics of LCP-Tacro™ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients Phase 2
Completed NCT05592106 - Gd-EOB-DTPA-enhanced T1 Map for Predicting Postoperative Liver Failure
Not yet recruiting NCT06014320 - Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease
Recruiting NCT04221672 - The Effect of Terlipressin on Recovery of Liver Function After Hepatectomy Phase 3
Completed NCT02635347 - Remote Ischemic Conditioning (RIC) in Recipients of Brain Death Donor Livers - A Feasibility and Safety Study N/A